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Facial expressions of basic emotions have been widely used to investigate the neural substrates of emotion processing, but little
is known about the exact meaning of subjective changes provoked by perceiving facial expressions. Our assumption was that
fearful faces would be related to the processing of potential threats, whereas angry faces would be related to the processing of
proximal threats. Experimental studies have suggested that serotonin modulates the brain processes underlying defensive
responses to environmental threats, facilitating risk assessment behavior elicited by potential threats and inhibiting fight or flight
responses to proximal threats. In order to test these predictions about the relationship between fearful and angry faces and
defensive behaviors, we carried out a review of the literature about the effects of pharmacological probes that affect 5-HT-
mediated neurotransmission on the perception of emotional faces. The hypothesis that angry faces would be processed as a
proximal threat and that, as a consequence, their recognition would be impaired by an increase in 5-HT function was not
supported by the results reviewed. In contrast, most of the studies that evaluated the behavioral effects of serotonin challenges
showed that increased 5-HT neurotransmission facilitates the recognition of fearful faces, whereas its decrease impairs the
same performance. These results agree with the hypothesis that fearful faces are processed as potential threats and that 5-HT
enhances this brain processing.
Key words: Facial expressions; Serotonin; Defensive behavior
Publication supported by FAPESP.
Received August 23, 2007. Accepted February 7, 2008
Introduction
Anxiety disorders have been related to abnormalities in
brain processes underlying defensive responses to envi-
ronmental threats (1,2). The neurotransmitter serotonin (5-
hydroxytryptamine, 5-HT) seems to play a significant role
in modulating defensive behavior. For instance, it has
been suggested that 5-HT would facilitate risk-assess-
ment behavior elicited by a potential threat, which has
been related to anxiety, by acting on the amygdala. In turn,
5-HT would inhibit fight or flight reactions to a proximal
threat related to panic by acting on the midbrain periaque-
ductal gray matter (3,4). Later, McNaughton and Corr (5)
argued that two defense systems – an approach defense
system that deals with potential threats and approach-
avoidance conflict and is related to anxiety, and an avoid-
ance defense system that commands withdrawal from a
distal threat (related to fear) and proximal danger (related
to panic) – are longitudinally distributed along the brain,
although the former is largely represented in the forebrain
and the latter in the hindbrain. In this view, the hypothesis
cited above on the dual role of 5-HT in defense was
preserved, with the approach defense system being stim-
ulated and the avoidance defense system being inhibited
by 5-HT.
The ability to identify facial expressions of emotion is
important for social functioning and adaptation, and its
study may contribute to the knowledge of the neurobiology
of emotions. Neuroimaging studies have provided sub-
stantial data about the neural substrate of emotional face
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recognition. The amygdala has been consistently acti-
vated by the perception of fearful faces (6-9), although it
can also be activated by other kinds of facial expressions,
such as disgust (7,10), sadness (11,12), happiness (9,11),
and anger (8,9,13). However, in direct contrast, activations
of the amygdala in response to fearful faces were greater
than in response to angry faces (8). The orbitofrontal
cortex (Brodman area = 47) also seems to be a common
brain region involved in the processing of different emo-
tional faces (10).
To understand the functional meaning of the brain
activation patterns depicted by neuroimaging evidence, it
would be necessary to know the adaptive meaning of each
facial expression, which is by no means an easy task.
Considering the processing of anxiety and related emo-
tions, the facial expressions of fear and anger are likely to
be of particular interest. It has been proposed that faces
expressing fear could be considered to be an ambiguous
stimulus (14), warning other people about a potential threat
in the environment. On the other hand, an angry face
directed toward a particular individual may represent a
proximal threat. If these assumptions are true, the above
mentioned hypothesis of a dual role of 5-HT in defense
allows the following predictions: 1) increased 5-HT func-
tion should facilitate the identification of fearful faces,
whereas reduced 5-HT function should impair the same
process; 2) increased 5-HT should impair, whereas lack of
5-HT should enhance, the identification of angry faces.
In order to test these predictions, we carried out a
review of the literature about the effects of pharmacologi-
cal probes that affect 5-HT-mediated neurotransmission
on the perception of fearful and angry faces. For compar-
ison, drug effects on the perception of other emotions are
also described.
Review protocol
A computer-based search of the literature indexed in
MEDLINE was made using the key words: face(s), facial,
expression, emotion, and serotonin, with no time limit. In
the first section, we have focused our survey on studies
that objectively measured the performance (accuracy and
speed) of healthy volunteers in the recognition of the
emotion portrayed in the facial expression, considering the
effect of a serotonergic drug compared to placebo. In the
second section, we have analyzed the results of neuroim-
aging studies, some of which include performance data
that have been discussed in the preceding section.
We excluded studies that evaluated the performance
of volunteers with current psychiatric disorders and stud-
ies that adopted faces to evaluate other cognitive func-
tions, such as memory. The survey was complemented
with the bibliography of the reviewed articles. For the
discussion, some references outside the above criteria
have also been included.
We selected 14 articles according to the criteria cited
above. Of these, ten (15-24) evaluated the effects of acute
manipulation of the 5-HT system. Three studies (25-27)
evaluated the effects of sub-chronic or chronic treatment
with 5-HT probes; one of them also included a noradrenergic
drug (25). Finally, one study (28) determined both the imme-
diate and four-day later effect of a single dose of ecstasy.
Behavioral data
The effects of serotonergic drugs on the identification
of facial expressions are summarized in Table 1.
The reduction of brain serotonergic function induced
by the acute intake of a mixture of essential amino acids
free of tryptophan, the precursor of 5-HT synthesis, im-
paired the recognition of fearful facial expressions by
healthy women, without any effect on other emotional
faces or on male volunteers (20). The same effect oc-
curred in s-carriers of the 5' promoter region (5-HTTLPR)
of the serotonin transporter of both genders, but not in LL
homozygotes (23). On the other hand, acute dietary sup-
plementation with tryptophan increased the perception of
facial expressions of happiness and fear in healthy female
volunteers (15). Chronic supplementation with tryptophan
(14 days) did not change the perception of fearful faces,
but facilitated the perception of happy expressions and
decreased the recognition of disgusted faces in female,
but not in male volunteers (27).
In the same direction, acute intravenous administration
of the selective serotonin reuptake inhibitor (SSRI) citalo-
pram (10 mg) facilitated the recognition of fearful and
happy faces by women (21). More recently, a similar effect
regarding fearful faces has been shown in both genders
after a single oral dose of citalopram (20 mg) (17). In
contrast, healthy female participants submitted to sub-
chronic treatment (7 days) with oral citalopram (20 mg/
day) showed impairment of the perception of facial expres-
sions of fear, anger and disgust compared to placebo (25).
A further study by the same research group (26) confirmed
the reduction of fearful faces recognition after a 7-day
treatment with citalopram in both genders.
Euthymic women with a previous history of major de-
pressive episodes recognized facial expressions of fear
more easily than healthy women without a history of de-
pression. The acute intravenous administration of citalo-
pram (10 mg) normalized the ability of the volunteers with
past depressive episodes to recognize fearful faces and
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increased the capacity of women without previous depres-
sion to recognize the same emotion (16).
In a naturalistic study, the acute administration of 3,4-
methylenedioxymethamphetamine (MDMA, “ecstasy”) to
volunteers of both genders increased the perception of
fearful expressions. However, after 4 days of drug with-
drawal, the opposite effect was observed, i.e., a decrease
in the recognition of fearful faces (28).
No effect of the 5-HT3 antagonist ondansetron on the
modulation of facial emotional expressions has been found
(22).
It is important to highlight that most of the reviewed
studies did not report changes in subjective feelings of
anxiety during the experimental procedures with seroto-
nergic challenges.
Neuroimaging data
Pharmacological functional magnetic resonance imag-
ing has become a very useful technique for investigating
the effects of drugs on brain metabolic activity through the
changes in the blood oxygen level-dependent signal. Nev-
ertheless, only a few studies have investigated the phar-
macological modulation of the hemodynamic response to
facial expressions so far. Neuroimaging results are sum-
marized in Table 2.
In an unconscious perception paradigm, where the
volunteers were asked just to make a gender categoriza-
tion of faces, Cools et al. (18) observed that tryptophan
depletion in healthy male volunteers enhanced amygdala
activation in response to fearful faces compared to happy
and neutral faces as a function of self-reported threat
sensitivity measured by BIS/BAS scales. These scales
have been developed to test the constructs of the behav-
ioral inhibition system and behavioral activation system
proposed by Gray and McNaughton (2).
In a similar paradigm of gender categorization, a single
dose (7.5 mg) of intravenous citalopram attenuated the
hemodynamic response of the right amygdala and right
orbitofrontal cortex to aversive (angry, disgusted and fear-
Table 1. Effects of serotonergic probes on the perception of basic emotional facial expressions by healthy volunteers.
Reference Method Emotion
Happiness Sadness Anger Fear Disgust Surprise
Harmer et al. (20) Tryptophan depletion; both genders — — — ↓* — —
Marsh et al. (23) Tryptophan depletion; both genders — — — ↓** — —
Attenburrow et al. (15) Tryptophan supplementation; only females ↑ — — ↑ — —
Murphy et al. (27) Tryptophan supplementation for 14 days; ↑* — — — ↓* —
both genders
Harmer et al. (21) Intravenous citalopram (10 mg); only females ↑ — — ↑ — Not evaluated
Browning et al. (17) Single dose of oral citalopram (20 mg); both — — — ↑ — —
genders
Bhagwagar et al. (16) Intravenous citalopram (10 mg); euthymic
females with or without a past history of major
depression
MD + placebo — — — ↑ — Not evaluated
MD + citalopram — — — — —
No MD + citalopram — — — ↑ —
Harmer et al. (25) Oral citalopram (20 mg) for 7 days; only females — — ↓ ↓ ↓ —
Harmer et al. (26) Oral citalopram (20 mg) for 7 days; both genders — — — ↓ — —
Harmer et al. (22) Ondansetron; both genders — — — — — —
Hoshi et al. (28) Ecstasy; both genders
Day 0 — — — ↑ — —
Day 4 — — — ↓ — —
↑ = increase of the identification of the facial emotion (lower number of errors and/or lower response time) in comparison to placebo;
↓ = decrease of the identification of the facial emotion (higher number of errors and/or higher response time) in comparison to placebo;
— = no differences between groups; *differences only among females; **significant only in s carriers. MD = major depression.
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ful) faces compared to neutral faces in male volunteers
(19). Pretreatment with citalopram (20 mg) for seven days
attenuated amygdala activation to fearful faces compared
to happy faces in volunteers of both genders (26).
In these neuroimaging studies, no drug effect was
observed on the task performed during scanning or on
subjective measures, except for a reduction of self-rated
hostility perception and behavior, evaluated by the Buss-
Durkee Hostility Inventory, which was reported after 7 days
of oral citalopram (26).
More recently, van der Veen et al. (24) replicated in
females the results obtained by Cools et al. (18), showing
a significant correlation between threat sensitivity (BIS
scale) and higher right amygdala activation by fearful
faces in contrast to happy faces under tryptophan deple-
tion. This study has also shown that the mood depression
caused by tryptophan depletion in healthy females with a
family history of depression was associated with impaired
performance of gender categorization of negative facial
expressions (fear, sadness and disgust) and with increased
activation of the right amygdala.
Conciliating the data from serotonergic
challenges on facial emotional expressions
Although their number is small, the articles reviewed
here point to a serotonergic modulation of the identification
of basic emotional facial expression by healthy volunteers.
Also, the lack of effect on subjective anxiety suggests that
the serotonergic modulation of facial expression process-
ing can occur independently of changes in and/or con-
scious recognition of the feelings aroused by emotional
faces.
The results obtained with drugs that interfere with
serotonergic neurotransmission reinforce the role of 5-HT
in the processing of anxiety and fear (3), since 9 of 11
studies that measured the behavioral effects of serotoner-
gic probes found changes in the ability to identify fearful
faces. In fact, in one study (22), the lack of effect could be
hypothesized a priori since, according to the Deakin and
Graeff’s hypothesis (3) on the dual role of 5-HT in defense,
the 5-HT3 receptor is not supposed to modulate anxiety or
fear processing. The processing of other emotions, such
Table 2. Effects of serotonergic probes on the BOLD-fMRI signal provoked by the perception of basic emotional facial expressions.
Sample Study design Drug fMRI task Facial Modulation of brain
expressions activation
Cools et al. (18) 12 male volunteers Double-blind; Tryptophan-depleting Block design; Fearful; ↑ Amygdala (fearful &
Placebo-controlled; drink 5 h prior to the Ekman faces; Happy; happy faces; fearful &
Crossover design fMRI session Gender categorization Neutral neutral faces) in threat-
sensitive volunteers
Del-Ben et al. (19) 12 male volunteers Single-blind; Intravenous Block design; Aversive ↓ Right OFC (BA47) and
Placebo-controlled; citalopram (7.5 mg/ Ekman faces; (fearful, right amygdala (aversive
Crossover design 7.5 min) 1 h prior to Gender categorization angry & & neutral faces)
the fMRI session disgusted);
Neutral
Harmer et al. (26) 24 volunteers Double-blind; Oral citalopram Block design; Fearful; ↓ Amygdala (fearful &
(14 females) Placebo-controlled; (20 mg) 7 days of Ekman faces; Happy happy faces)
Between group treatment Gender categorization
comparison
Van der Veen et al. 33 female volunteers Double-blind; Tryptophan-depleting Event-related design; Fearful; ↑ Right amygdala
(24) Placebo-controlled; drink 5 h prior to the Ekman faces; Sad; (fearful & happy faces)
Crossover design fMRI session Intensity of emotional Disgusted; in threat-sensitive
expression; Happy volunteers;
Gender categorization ↑ Right amygdala and
right ventromedial
prefrontal cortex in
volunteers with family
history of depression
↑ = increase of the neuronal response by the serotonergic probe; ↓ = decrease of the neuronal response by the serotonergic probe. BOLD-fMRI = blood
oxygen level-dependent-functional magnetic resonance imaging; OFC = orbitofrontal cortex.
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as happiness and disgust, also seems to be under the
influence of the 5-HT system, although the results reported
so far are less consistent.
Two studies (20,27) suggested a sexual dimorphism in
the 5-HT modulation of emotional processing since the
effects of either tryptophan depletion or tryptophan supple-
mentation were observed only in female volunteers. How-
ever, it is impossible to further explore this hypothesis,
given that most of the studies carried out so far with
serotonergic manipulation have included just females in
their samples.
Although MDMA releases dopamine and noradrena-
line, its main mechanism of action is by serotonergic
neurotransmission, inhibiting 5-HT reuptake in the neuron
membrane and stimulating the release of 5-HT stored in
pre-synaptic vesicles (29). Moreover, MDMA decreases 5-
HT synthesis by means of tryptophan-hydroxylase inhibi-
tion, causing 5-HT depletion during the days following its
administration. Correlating with these actions, in the re-
sults reviewed, MDMA facilitated the recognition of fearful
faces after acute administration, whereas four days later
the perception of fearful faces was impaired (29).
The effects of manipulation of the levels of tryptophan,
the precursor of serotonin synthesis, in the diet show a
similar pattern, at least in healthy female volunteers (15)
and in volunteers of both genders carrying the s genotype
of the serotonin transporter (23). Thus, intake of tryp-
tophan, and the consequent increase in 5-HT availability
have been shown to facilitate the identification of fearful
faces (15,23), whereas the decrease of 5-HT function by
tryptophan depletion impairs the identification of fear ex-
pressions (20).
Acute intravenous administration of citalopram has
been shown to facilitate the perception of fearful faces
(21), an effect similar to that of tryptophan intake and of
acute administration of ecstasy, and opposite to that of
tryptophan depletion and on the fourth day after ecstasy.
Taken together, these data suggest that intravenous injec-
tion of citalopram increases 5-HT availability. The clinical
efficacy of the SSRIs is attributed to enhanced serotoner-
gic neurotransmission, which in turn depends on the de-
sensitization of 5-HT1A autosomal receptors occurring
nearly two weeks after repeated daily administration of
these drugs (30). In fact, the beginning of treatment with
SSRIs is supposed to reduce 5-HT function, a fact that may
be associated with the worsening of anxiety symptoms
commonly observed in clinical practice (31). In contrast,
sub-chronic treatment with citalopram for 7 days has been
shown to reduce the recognition of fearful faces (25).
These results may be related to downstream neuroadaptive
changes that occur with repeated administration of antide-
pressants, such as the down-regulation of specific 5-HT
receptors.
Experimental data have shown that, following the ad-
ministration of SSRIs, there is a greater increase in extra-
cellular 5-HT in the raphe nuclei than in the cortex (32).
Therefore, it is possible that a low acute dose of an SSRI
would preferentially increase 5-HT concentration near the
cell bodies of serotonergic neurons, reducing their firing
rate due to the activation of somatodendritic autoreceptors
(33) and, hence, decreasing 5-HT release and lower syn-
aptic 5-HT concentration postsynaptically. On the other
hand, microdialysis studies in animals have shown in-
creases in cortical extracellular 5-HT following acute SSRI
administration (34-36). Moreover, intravenous injection of
low doses of citalopram in healthy volunteers has resulted
in plasma cortisol and prolactin increases (37,38), taken
as an indirect measure of 5-HT function in the brain.
Reported neuroimaging results are more difficult to
interpret since few published studies have evaluated the
pharmacological modulation of hemodynamic responses
provoked by facial expression recognition. Moreover, the
differences in the features of the samples studied, in the
procedure of image acquisition and analysis, and in the
paradigms of psychological activation used impair the
comparison of the results reported.
Although behavioral data showed that acute citalopram
increased, while chronic citalopram decreased the identifi-
cation of fearful faces, both the 7-day administration of
citalopram (21) and the acute intravenous dose of citalo-
pram (19) decreased amygdala activation in response to
aversive faces, an opposite effect to that of tryptophan
depletion (18,24). Nevertheless, the effect of tryptophan
depletion occurred only in threat-sensitive volunteers and
therefore these seemingly contradictory results between
behavioral and neuroimaging data may be due to the inter-
ference of personality traits with emotional processing.
Assuming a direct correlation between neuronal acti-
vation measured by functional magnetic resonance imag-
ing and the performance of emotional face recognition, we
would expect increased 5-HT function to enhance the
hemodynamic response of the amygdala to fearful faces.
However, the reported results have shown that increasing
5-HT availability with citalopram decreased (19,21),
whereas decreasing 5-HT with tryptophan depletion en-
hanced, amygdala activation (18,24).
In seeming contrast to the above conclusion, clinical
studies have pointed to higher activation of the amygdala
by emotional facial expressions in anxiety-prone healthy
volunteers (39) and in patients with anxiety disorders (40)
than in controls, and there is evidence from studies with
depressive patients that antidepressant treatment normal-
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izes the enhanced activation of the amygdala in response
to negative faces (41,42). Even so, reported data have
shown that the changes in fearful face recognition caused
by 5-HT probes have not been associated with changes in
subjective measures of anxiety. Hence, we do not know
whether the improvement in the recognition of fearful faces
is associated with higher levels of anxiety or whether its
impairment is related to less subjective anxiety of the
perceiving subject.
Another weakness is that there are important differ-
ences between the experimental paradigms of the neuro-
imaging studies reviewed above. For instance, while sub-
chronic treatment with citalopram (21) has included volun-
teers of both genders, acute administration of citalopram
(19) has been made only in male volunteers, and there is
considerable evidence pointing to sexual dimorphism in
emotional processing (43). Also, the features of the func-
tional magnetic resonance imaging technique itself have to
be taken into account when interpreting these results. In
fact, the meaning of the recorded changes in the hemody-
namic response of specific brain areas caused by pharma-
cological modulation of neuropsychological tasks is not
straightforward. Increases in the blood oxygen level-de-
pendent signal are thought to be an index of increased
neuronal metabolism measured by oxygen consumption.
The enhancement of neuronal metabolism caused by a
pharmacological challenge can reflect both an improve-
ment of the performance (“working better”) and the need
for an extra effort to achieve the same level of function
(“working harder”). More studies correlating neuroimaging
and performance data are needed to clarify this issue.
Conclusion
The behavioral data reviewed here indicate that in-
creased 5-HT neurotransmission facilitates the recogni-
tion of fearful faces, whereas its decrease impairs the
same performance, without a significant change in subjec-
tive anxiety. These results are in agreement with the
hypothesis that fearful faces are processed as potential
threats and that 5-HT facilitates such brain processing.
In contrast, the hypothesis that angry faces would be
processed as a proximal threat and, as a consequence,
their recognition would be impaired by an increase of 5-HT
function was not supported by the results reviewed since
only 1 of 10 studies with serotonergic probes found a
significant drug effect on the perception of angry faces.
Finally, the neuroimaging results reported thus far on
the effect of 5-HT probes on the brain processing of emo-
tional face recognition are rather inconsistent, more stud-
ies being needed in this field.
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